Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2023; 11(35): 8425-8430
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8425
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8425
Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report
Hiroyasu Yamashiro, Nao Morii, Department of Breast Surgery, Tenri Hospital, Nara, Tenri 632-8552, Japan
Author contributions: Yamashiro H and Morii N contributed to manuscript writing and editing; all authors have read and approved the final manuscript.
Informed consent statement: Although the informed written consent cannot be obtained because the patient has already died, I can state clearly that this case report does not contain information that could identify the individual patient.
Conflict-of-interest statement: Hiroyasu Yamashiro received honoraria from Chugai, Novartis, Takeda, Eisai, Daiichi-Sankyo and AstraZeneca, Pfizer, Eli Lilly and Kyowa-Kirinoutside this work. Nao Morii received honoraria from Eli Lilly outside this work.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hiroyasu Yamashiro, MD, PhD, Director, Department of Breast Surgery, Tenri Hospital, No. 200 Mishima-cho, Nara, Tenri 632-8552, Japan.
Received: October 11, 2023
Peer-review started: October 11, 2023
First decision: October 24, 2023
Revised: November 4, 2023
Accepted: November 30, 2023
Article in press: November 30, 2023
Published online: December 16, 2023
Processing time: 64 Days and 0.4 Hours
Peer-review started: October 11, 2023
First decision: October 24, 2023
Revised: November 4, 2023
Accepted: November 30, 2023
Article in press: November 30, 2023
Published online: December 16, 2023
Processing time: 64 Days and 0.4 Hours
Core Tip
Core Tip: In this case report, we address the critical issue of limited therapeutic options for HER2-negative breast cancer patients with brain metastases. We present a case of a woman with estrogen receptor-positive, HER2-negative breast cancer who initially exhibited an encouraging response to abemaciclib and letrozole therapy for brain metastases. However, this treatment had to be discontinued due to drug-induced lung damage. This study reports the challenges of achieving a balance between efficacy and adverse events in managing brain metastases and highlights the need for alternative treatment strategies in this patient population.